Picon G, Falque V, Caniot E, Dispa C, Bourlier-Najean B, Legre R, Viard L, Guys J M
l'Unité d'Hémodialyse Pédiatrique, Hôpital d'Enfants de la Timone, Marseille.
Ann Pediatr (Paris). 1991 Mar;38(3):157-64.
In order to analyze the place of dialysis in a hemodialysis/transplantation program, the duration of each treatment modality, mortality rate and quality of inclusion in the social network were studied. Complications which arose during hemodialysis were evaluated by comparing the 1970's and the 1980's. Sixty children with terminal renal failure, aged 3 to 15 years, were entered in a hemodialysis/transplantation program between May 1971 and December 1988. Patients were followed up until December 1989. Among the 47 (78%) survivors at the end of the follow-up period, 25 had a functioning renal transplant and 22 were undergoing dialysis. Among the 13 deaths, 7 occurred during renal transplantation or immediately after loss of the transplant and 6 occurred under dialysis. Mean duration of treatment, including both dialysis and transplantation, was 7 years 11 months. Mean time spent under dialysis was 4 years 9 months. Time spent with a functioning transplant was 3 years 10 months for the 46 transplant recipients. Mean time spent on the transplant waiting list fell from 3 years 6 months before 1980 to 2 years after 1980. Virtually no cases of renal osteodystrophy, acute arterial hypertension or hepatitis B were seen after 1980 as a result of the use of higher-potency vitamin D derivatives, recent antihypertensive drugs including ACE inhibitors, and the Hevac B vaccine. Similarly, safety and patient comfort during dialysis improved substantially, as well as the quality of rehabilitation. Growth remained a significant problem although improvements can be expected to occur in the near future. Hemodialysis is an indispensable complement to transplantation.(ABSTRACT TRUNCATED AT 250 WORDS)
为分析透析在血液透析/移植项目中的地位,研究了每种治疗方式的持续时间、死亡率以及融入社交网络的质量。通过比较20世纪70年代和80年代来评估血液透析期间出现的并发症。1971年5月至1988年12月期间,60名3至15岁的终末期肾衰竭儿童进入了血液透析/移植项目。对患者进行随访至1989年12月。在随访期结束时的47名(78%)幸存者中,25人有功能良好的肾移植,22人正在接受透析。在13例死亡病例中,7例发生在肾移植期间或移植失败后不久,6例发生在透析期间。包括透析和移植在内的平均治疗时间为7年11个月。透析的平均时间为4年9个月。46名移植受者有功能良好的移植的时间为3年10个月。移植等待名单上的平均时间从1980年前的3年6个月降至1980年后的2年。由于使用了高效能维生素D衍生物、包括血管紧张素转换酶抑制剂在内的新型抗高血压药物以及乙肝疫苗,1980年后几乎未见肾性骨营养不良、急性动脉高血压或乙肝病例。同样,透析期间的安全性和患者舒适度大幅提高,康复质量也有所提高。生长仍然是一个重大问题,不过预计在不久的将来会有所改善。血液透析是移植不可或缺的补充。(摘要截选至250字)